Glimepiride detailed information

Glimepiride detailed information

Clinical data
ATC code	A10BB12 (WHO)
Pharmacokinetic data
Protein binding	>99.5%
Identifiers
IUPAC name 3-ethyl-N,N-bis (3-ethyl-4-methyl-2-oxo-5H-pyrrol-2-yl)- 4-methyl-2-oxo-5H-pyrrole-1- carboxamide
CAS Number	93479-97-1
PubChem CID	3476
DrugBank	APRD00381
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C24H34N4O5S
Molar mass	490.617 g/mol

WikiDoc Resources for Glimepiride detailed information
Articles
Most recent articles on Glimepiride detailed information Most cited articles on Glimepiride detailed information Review articles on Glimepiride detailed information Articles on Glimepiride detailed information in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Glimepiride detailed information Images of Glimepiride detailed information Photos of Glimepiride detailed information Podcasts & MP3s on Glimepiride detailed information Videos on Glimepiride detailed information
Evidence Based Medicine
Cochrane Collaboration on Glimepiride detailed information Bandolier on Glimepiride detailed information TRIP on Glimepiride detailed information
Clinical Trials
Ongoing Trials on Glimepiride detailed information at Clinical Trials.gov Trial results on Glimepiride detailed information Clinical Trials on Glimepiride detailed information at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Glimepiride detailed information NICE Guidance on Glimepiride detailed information NHS PRODIGY Guidance FDA on Glimepiride detailed information CDC on Glimepiride detailed information
Books
Books on Glimepiride detailed information
News
Glimepiride detailed information in the news Be alerted to news on Glimepiride detailed information News trends on Glimepiride detailed information
Commentary
Blogs on Glimepiride detailed information
Definitions
Definitions of Glimepiride detailed information
Patient Resources / Community
Patient resources on Glimepiride detailed information Discussion groups on Glimepiride detailed information Patient Handouts on Glimepiride detailed information Directions to Hospitals Treating Glimepiride detailed information Risk calculators and risk factors for Glimepiride detailed information
Healthcare Provider Resources
Symptoms of Glimepiride detailed information Causes & Risk Factors for Glimepiride detailed information Diagnostic studies for Glimepiride detailed information Treatment of Glimepiride detailed information
Continuing Medical Education (CME)
CME Programs on Glimepiride detailed information
International
Glimepiride detailed information en Espanol Glimepiride detailed information en Francais
Business
Glimepiride detailed information in the Marketplace Patents on Glimepiride detailed information
Experimental / Informatics
List of terms related to Glimepiride detailed information

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Glimepiride is a medium-to-long acting sulfonylurea anti-diabetic drug. It is marketed as Amaryl by Sanofi-Aventis. Glimepiride is the first third-generation sulfonylurea, and is very potent.

Indications

Type 2 diabetes (NIDDM).

Adverse effects

Main article: Sulfonylurea

GI disturbance, rarely thrombopenia, leucopenia, haemolytic anaemia, occasionally allergic. In the initial weeks of treatment, the risk of hypoglycemia may be increased.

Contraindications

Hypersensitivity to glimepiride or other sulfonylureas.

Interactions

With NSAIDs like Salicylates, Sulphoamides, Chlorampenicol, coumarin and probencid may potentiate the hypoglycemic action of glimepride. Thiazides, other diuretics, phothiazides, thyroid products, oral contraceptives, phenytoin tend to produce hyperglycemia.

Pharmacology

With Glimepiride GI absorption is complete with no interference of meals. Significant absorption of glimepiride was seen within one hour, and distributed through out the body, bound to the plasma protein to an extended of 99.5% and it is metabolised by oxidative biotransformation and 60% is excreted in the urine, and remaining is excreted in the feces.

Mechanism of action

Main article: Sulfonylurea

Glimepiride distinctly lower the blood glucose level by both defects of NIDDM, by stimulating pancreatic beta cells to produce more insulin and induced increased activity of peripheral insulin intra cellular receptor. Template:SIB Template:Oral hypoglycemics

Template:WikiDoc Sources